An Open-Label Safety Study of Lapatinib Plus Trastuzumab Plus Paclitaxel in First-Line HER2-Positive Metastatic Breast Cancer

BACKGROUND. Recent data support the hypothesis that combining lapatinib and trastuzumab with taxane chemotherapy may offer added clinical benefit to patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC). This study examined the safety of the triplet co...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Esteva, Francisco J., Franco, Sandra X., Hagan, Maura K., Brewster, Abenaa M., Somer, Robert A., Williams, Will, Florance, Allison M., Turner, Simon, Stein, Steven, Perez, Alejandra
Formato: Artigo
Idioma:Inglês
Publicado em: AlphaMed Press 2013
Assuntos:
Breast Cancer
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4063391/
https://ncbi.nlm.nih.gov/pubmed/23697602
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2012-0129
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados